Merck has decided to suspend its Phase 3 trial that was assessing a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) as a first-line therapy for patients with advanced non-small cell lung cancer (NSCLC), the company announced in a press release. The decision to halt the study was based on recommendations from an independent data monitoring committee, which concluded the benefit-risk profile of the combination therapy did not warrant the study’s continuation. The trial, called KEYNOTE-598 (NCT03302234),…
You must be logged in to read/download the full post.
The post Merck Halts Phase 3 Trial on Yervoy-Keytruda Combo in Advanced Lung Cancer appeared first on BioNewsFeeds.